Comparative In Vivo Activities of Cefsulodin, Sulbenicillin, and Gentamicin Against
            <i>Pseudomonas aeruginosa</i>

Kondo, Masahiro; Tsuchiya, Kanji

doi:10.1128/aac.14.1.151

Cited by 9 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, cefsulodin {3-(4-carbamoyl-1-pyridiniomethyl)-7,8 -(D-a-sulfophenylacetamido) -ceph-3-em-4-carboxylate monosodium salt) did not show bacteriolytic activity and has about 10 times stronger MIC and bactericidal activities against P. aeruginosa than carbenicillin and sulbenicillin. The protective activity in mice of cefsulodin was about 30 times more potent than those of carbenicilin and sulbenicillin (5,9). It has been reported that the bactericidal activity does not indicate the bacteriolytic activity (1, 2, 10).…”

Section: Discussionmentioning

confidence: 97%

SCE-963, a New Broad-Spectrum Cephalosporin: In Vitro and In Vivo Antibacterial Activities

Tsuchiya

Kida

Kondo

et al. 1978

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

SCE-963 {7beta-[2-(2-aminothiazol-4-yl)acetamido]-3-[({1-(2-dimethylaminoethyl)- 1H-tetrazol-5-yl}thio)methyl]-ceph-3-em-4-carboxylic acid}, a new semisynthetic cephalosporin, showed excellent antibacterial activity against gram-positive and gram-negative bacteria, including Haemophilus influenzae, indole-positive Proteus, Enterobacter species, and Citrobacter freundii. The minimum inhibitory concentrations of SCE-963 against most strains of clinically isolated Escherichia coli, Klebsiella pneumoniae, H. influenzae, and Proteus mirabilis were within the range of 0.2 to 0.78 mug/ml. These activities were about 10 times more potent than those of cefazolin, cephaloridine, and cephalothin. Variations in pH, addition of horse serum, and type of growth medium had no significant effect on the activity of the cephalosporin, but the inoculum size elicited a considerable effect on the activity of beta-lactamase-producing strains of bacteria. SCE-963 exerted bactericidal and bacteriolytic effects on Staphylococcus aureus and E. coli. The pronounced in vitro activity was reflected in the remarkable protection in mice infected with a wide range of gram-negative bacteria, such as E. coli, K. pneumoniae, P. mirabilis, Proteus vulgaris, Proteus morganii, and Proteus rettgeri. The protective effects of SCE-963 in mice infected with E. coli, K. pneumoniae, and P. vulgaris varied according to the challenge dose. The activity of SCE-963 was far more potent when the drug was administered parenterally rather than orally.

show abstract

Section: Discussionmentioning

confidence: 97%

SCE-963, a New Broad-Spectrum Cephalosporin: In Vitro and In Vivo Antibacterial Activities

Tsuchiya

Kida

Kondo

et al. 1978

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cefsulodin is a third-generation cephalosporin with high in vitro activity against P. aeruginosa [mean MIC 8 mg/L, Kondo & Tsuchiya (1978)]. It also has moderate activity against Staphylococci (median MIC 6.25 mg/L) [Glupczynski et al 1985].…”

Section: Cefsulodinmentioning

confidence: 99%

Antibiotic Pharmacokinetics in Cystic Fibrosis

1987

Clinical Pharmacokinetics

149

View full text Add to dashboard Cite

Antibiotics are administered to cystic fibrosis patients for chronic endobronchial infection complicated by frequent exacerbations. Agents active against Staphylococcus aureus, Pseudomonas aeruginosa or both are administered. Serum antibiotic concentrations were measured in cystic fibrosis patients in an effort to optimise antibiotic dose and frequency. This led to the observation that cystic fibrosis subjects had (in general) a larger Vd and increased total body clearance of beta-lactams and aminoglycosides than non-cystic fibrosis subjects. The larger Vd is mainly due to the increased amount of lean body mass per kg bodyweight, although increased tissue binding may also account for part of this. The increased total body clearance of beta-lactams appears to be due to increased renal elimination, particularly tubular secretion. Decreased tubular reabsorption and increased non-renal clearance contribute to the increased total body clearance of metabolised beta-lactams and aminoglycosides. However, the lack of concomitant controls in many studies make these generalisations tentative. The result of the apparent cystic fibrosis-specific differences is lower peak serum antibiotic concentrations, a smaller AUC, and a shorter elimination half-life than non-cystic fibrosis subjects. Since sputum (and bronchial mucosal) concentration is dependent on the peak serum concentration (and AUC), cystic fibrosis subjects require larger doses of most antibiotics more frequently. Newer quinolones may be an exception. Studies comparing the efficacy and safety of larger and more frequent antibiotic doses to conventional therapy are not available. Although it appears logical to mimic serum antibiotic concentrations found in non-cystic fibrosis subjects, the lack of information on the ideal sputum concentration versus time curve should temper our enthusiasm for cystic fibrosis-specific dosage regimens.

show abstract

Simultaneous Determinations of Cefsulodin and Cefotiam in Serum and Bone Marrow Blood by High-Performance Liquid Chromatography

Yamamura

Nakao

Yamada

et al. 1983

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Comparative In Vivo Activities of Cefsulodin, Sulbenicillin, and Gentamicin Against Pseudomonas aeruginosa

Cited by 9 publications

References 7 publications

SCE-963, a New Broad-Spectrum Cephalosporin: In Vitro and In Vivo Antibacterial Activities

SCE-963, a New Broad-Spectrum Cephalosporin: In Vitro and In Vivo Antibacterial Activities

Antibiotic Pharmacokinetics in Cystic Fibrosis

Simultaneous Determinations of Cefsulodin and Cefotiam in Serum and Bone Marrow Blood by High-Performance Liquid Chromatography

Contact Info

Product

Resources

About